Nazli G.Rahim Ph.D.


硅谷 + 1.650.687.4198

Nazli Rahim's practice includes the preparation and prosecution of domestic and foreign patent applications in the fields of biotechnology, immunology, oncology, cell biology, and pharmaceuticals. She also has experience in conducting IP due diligence evaluations, patentability analysis, and freedom to operate analysis.

Nazli has drafted and prosecuted patent applications directed to CRISPR gene editing, antibody therapeutics, enzyme replacement therapies, CAR-T cell therapies, drug formulations, cancer therapeutics, and next-generation sequencing.

Prior to joining Jones Day, Nazli obtained her Ph.D. in genetics at Caltech, where she studied the molecular mechanisms underlying proteolysis. She has more than 10 years of industry experience and has conducted research at the European Molecular Biology Laboratory, the Cancer Research Center of Lyon, The Scripps Research Institute, and Genentech.


  • ToolGen faces off in two patent interferences involving CRISPR/Cas9 applicationJones Day is representing ToolGen, Inc. in two patent interferences involving CRISPR/Cas9 technology.
  • ToolGen obtains ex parte PTAB appeal victory reversing examiner's rejections in CRISPR patent applicationOn June 22, 2020, Jones Day obtained a decision on behalf of ToolGen, Inc. at the United States Patent Trial and Appeal Board ("PTAB") reversing all of the examiner's obviousness rejections of the claims in ToolGen's U.S. Patent Application No. 14/685,510 (Appeal No. 2019-001990).
  • Royalty Pharma acquires EMGALITY® royalty from Arteaus Therapeutics for $260 millionJones Day advised Royalty Pharma, the industry leader in acquiring pharmaceutical royalties, in its $260 million acquisition of the royalty interest held by Arteaus Therapeutics, LLC on future global net sales of Eli Lilly and Company’s EMGALITY® (galcanezumab), an anti-CGRP antibody for the prevention of migraine.